Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ARMP logo ARMP
Upturn stock ratingUpturn stock rating
ARMP logo

Armata Pharmaceuticals Inc (ARMP)

Upturn stock ratingUpturn stock rating
$1.9
Last Close (24-hour delay)
Profit since last BUY-15.56%
upturn advisory
WEAK BUY
BUY since 28 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ARMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $9

1 Year Target Price $9

Analysts Price Target For last 52 week
$9Target price
Low$0.9
Current$1.9
high$3.42

Analysis of Past Performance

Type Stock
Historic Profit -73.52%
Avg. Invested days 24
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 72.39M USD
Price to earnings Ratio -
1Y Target Price 9
Price to earnings Ratio -
1Y Target Price 9
Volume (30-day avg) 1
Beta 0.97
52 Weeks Range 0.90 - 3.42
Updated Date 06/30/2025
52 Weeks Range 0.90 - 3.42
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.4

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -9.07%
Operating Margin (TTM) -1668.23%

Management Effectiveness

Return on Assets (TTM) -24.32%
Return on Equity (TTM) -3439.35%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 195356958
Price to Sales(TTM) 15.4
Enterprise Value 195356958
Price to Sales(TTM) 15.4
Enterprise Value to Revenue 148.14
Enterprise Value to EBITDA 14.49
Shares Outstanding 36193500
Shares Floating 11019467
Shares Outstanding 36193500
Shares Floating 11019467
Percent Insiders 69.59
Percent Institutions 2.05

Analyst Ratings

Rating 1
Target Price 9
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Armata Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Armata Pharmaceuticals, Inc., (ticker ARMP) founded in 2003 (originally as AmpliPhi Biosciences), is a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections. They aim to combat the rise of antimicrobial resistance through phage-based therapies.

business area logo Core Business Areas

  • Bacteriophage Therapeutics Development: Armata focuses on developing and commercializing bacteriophage-based therapies for antibiotic-resistant bacterial infections. This includes identifying, engineering, and manufacturing phages targeting specific pathogens.
  • Phage Discovery and Screening: The company engages in the discovery and characterization of novel bacteriophages with therapeutic potential. They have a library of phages that are screened for activity against various bacterial strains.

leadership logo Leadership and Structure

Sven H. Dreesbach is the CEO of Armata Pharmaceuticals, Inc. The company has a typical biotech organizational structure with departments dedicated to research and development, manufacturing, clinical trials, and regulatory affairs.

Top Products and Market Share

overview logo Key Offerings

  • AP-PA02: A bacteriophage therapeutic targeting Pseudomonas aeruginosa infections, currently in Phase 1b/2a clinical trials. Competitors include traditional antibiotics and other companies developing novel antimicrobials.
  • AP-SA02: A bacteriophage therapeutic targeting Staphylococcus aureus infections, including methicillin-resistant Staphylococcus aureus (MRSA). Competitors include traditional antibiotics and other companies developing novel antimicrobials.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is facing a growing threat from antibiotic-resistant bacteria, creating a significant unmet medical need. This has led to increased investment and research in alternative therapies, including bacteriophage therapy.

Positioning

Armata is positioned as a leader in the development of bacteriophage-based therapies. Their focus on pathogen-specific phages gives them a potential advantage over broad-spectrum antibiotics.

Total Addressable Market (TAM)

The TAM for antimicrobial resistance is estimated to be in the tens of billions of dollars. Armata aims to capture a portion of this market by providing targeted phage therapies. The exact size depends on regulatory approvals and market penetration.

Upturn SWOT Analysis

Strengths

  • Proprietary phage library
  • Expertise in bacteriophage therapy
  • Focus on specific pathogens
  • Addressing unmet medical need

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial success
  • Relatively small size
  • Novelty of phage therapy, regulatory hurdles

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Government funding for antimicrobial resistance research
  • Increasing acceptance of phage therapy

Threats

  • Failure in clinical trials
  • Competition from other antimicrobial therapies
  • Regulatory challenges
  • Emergence of phage-resistant bacteria

Competitors and Market Share

competitor logo Key Competitors

  • CARS
  • SNGX
  • ADTX

Competitive Landscape

Armata competes with companies developing traditional antibiotics and other novel antimicrobial therapies. They have a competitive advantage in the phage therapy space.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by research and development activities, clinical trial progress, and fundraising efforts.

Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approvals, and commercialization of phage therapies. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include advancing clinical trials for AP-PA02 and AP-SA02, expanding the phage library, and seeking partnerships.

Summary

Armata Pharmaceuticals is a biotechnology company focusing on bacteriophage therapies for antibiotic-resistant infections and holds promise. Its success hinges on clinical trial results, regulatory approvals, and partnerships. Challenges remain in securing funding and navigating the regulatory landscape, but their focus on phage therapy positions them in a market with unmet medical needs. The success of clinical trials will have a great effect on the future of the company.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Armata Pharmaceuticals SEC Filings (10-K, 10-Q)
  • Company Website
  • Analyst Reports
  • Industry News and Publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data should be verified with official SEC filings. The AI rating is based on available information and inherent uncertainties.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Armata Pharmaceuticals Inc

Exchange NYSE MKT
Headquaters Los Angeles, CA, United States
IPO Launch date 2011-03-09
CEO & Director Dr. Deborah L. Birx M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 60
Full time employees 60

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.